hydroxychloroquine has been researched along with Innate Inflammatory Response in 63 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effect of hydroxychloroquine (HCQ) on skeletal muscle and liver insulin sensitivity, insulin clearance, inflammation and adipokines." | 9.41 | The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: A randomized trial. ( DeLany, JP; Helbling, NL; Miller, RG; Toledo, FGS; Zhang, Y, 2021) |
| "We examined the effect of an immunomodulator hydroxychloroquine, also known as a Nurr1 ligand and an autophagy inhibitor, on a mouse model of intracerebral hemorrhage (ICH)." | 8.12 | Hydroxychloroquine improves motor function and affords neuroprotection without inhibition of inflammation and autophagy in mice after intracerebral hemorrhage. ( Ichihara, Y; Katsuki, H; Kinoshita, K; Kurauchi, Y; Seki, T; Yoshimizu, A, 2022) |
| " As a proof-of-concept, a complex of hydroxychloroquine (HCQ) with sulfonated azocalix[4]arene (HCQ@SAC4A) is prepared to treat rheumatoid arthritis (RA) in a combined fashion." | 8.12 | Drug in Drug: A Host-Guest Formulation of Azocalixarene with Hydroxychloroquine for Synergistic Anti-Inflammation. ( Geng, WC; Guo, DS; Hu, XY; Kong, X; Li, HB; Li, S; Ma, R; Zhang, C, 2022) |
| "Hydroxychloroquine (HCQ) suppresses an interleukin-1β-granulocyte-macrophage colony-stimulating factor cytokine axis, reported to be dysregulated in peripheral blood mononuclear cells of acute rheumatic fever patients ex vivo." | 7.96 | The Treatment of Acute Rheumatic Fever: Novel Use of Hydroxychloroquine. ( Concannon, A; Davidakova, S; Malcolm, J; Martin, WJ; Moreland, NJ; Webb, R; Wilson, NJ, 2020) |
| " Therefore, if this unique immune quiescent state can be pharmacologically induced locally, it will provide an excellent women-oriented strategy against HIV infection To our knowledge, this is the first research article evaluating in vivo, an innovative trackable implant that can provide controlled delivery of hydroxychloroquine (HCQ) to successfully attenuate vaginal T lymphocyte activation and inflammation in a rabbit model as a potential strategy to induce an "immune quiescent" state within the FGT for the prevention of HIV infection." | 7.88 | Implant delivering hydroxychloroquine attenuates vaginal T lymphocyte activation and inflammation. ( Chen, Y; Fowke, KR; Ho, EA; Lajoie, J; Rickey, DW; Traore, YL; Yang, S, 2018) |
| " Hydroxychloroquine, an original antimalarial drug, prevents inflammation caused by lupus erythematosus and rheumatoid arthritis." | 7.83 | Hydroxychloroquine, a promising choice for coronary artery disease? ( Bai, X; Li, R; Liu, J; Liu, M; Ma, Q; Sun, L; Wei, Y; Wu, Y; Yang, Y; Yuan, Z; Zhang, L; Zhao, Q; Zhou, J, 2016) |
| " Hydroxychloroquine (HCQ), an anti-inflammatory drug, has been shown to have multiple pleiotropic actions relevant to atherosclerosis." | 7.81 | Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease. ( Apostolov, EO; Bose, C; Fahmi, T; Karaduta, OK; Kaushal, GP; Segal, MS; Shah, SV; Shukla, AM, 2015) |
| "To determine the effect of hydroxychloroquine (HCQ) on skeletal muscle and liver insulin sensitivity, insulin clearance, inflammation and adipokines." | 5.41 | The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: A randomized trial. ( DeLany, JP; Helbling, NL; Miller, RG; Toledo, FGS; Zhang, Y, 2021) |
| " We found statistically significant improvement of pain and stiffness with methotrexate, especially in knee OA." | 5.22 | Effect of disease-modifying anti-rheumatic drugs in osteoarthritis: A meta-analysis. ( Mathieu, S; Sellam, J; Soubrier, M; Tournadre, A, 2022) |
| " In fact, two of the actually used drugs against SARS-CoV2, such as chloroquine and the combination lopinavir/ritonavir, might determine a QT (the time from the start of the Q wave to the end of the T wave) interval prolongation and they show several interactions with antiarrhythmic drugs and antipsychotic medications, making them prone to an increased risk of developing arrhythmias." | 5.12 | COVID-19 and the burning issue of drug interaction: never forget the ECG. ( Cameli, M; Cameli, P; Franchi, F; Mandoli, GE; Menci, D; Mondillo, S; Sciaccaluga, C; Sisti, N; Valente, S, 2021) |
| "We examined the effect of an immunomodulator hydroxychloroquine, also known as a Nurr1 ligand and an autophagy inhibitor, on a mouse model of intracerebral hemorrhage (ICH)." | 4.12 | Hydroxychloroquine improves motor function and affords neuroprotection without inhibition of inflammation and autophagy in mice after intracerebral hemorrhage. ( Ichihara, Y; Katsuki, H; Kinoshita, K; Kurauchi, Y; Seki, T; Yoshimizu, A, 2022) |
| " As a proof-of-concept, a complex of hydroxychloroquine (HCQ) with sulfonated azocalix[4]arene (HCQ@SAC4A) is prepared to treat rheumatoid arthritis (RA) in a combined fashion." | 4.12 | Drug in Drug: A Host-Guest Formulation of Azocalixarene with Hydroxychloroquine for Synergistic Anti-Inflammation. ( Geng, WC; Guo, DS; Hu, XY; Kong, X; Li, HB; Li, S; Ma, R; Zhang, C, 2022) |
| " Hydroxychloroquine is an immune modulating drug that is considered safe in pregnancy." | 4.12 | Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro. ( Beard, S; Binder, N; Brownfoot, FC; Hannan, N; Harper, A; Kadife, E, 2022) |
| "Hydroxychloroquine (HCQ) suppresses an interleukin-1β-granulocyte-macrophage colony-stimulating factor cytokine axis, reported to be dysregulated in peripheral blood mononuclear cells of acute rheumatic fever patients ex vivo." | 3.96 | The Treatment of Acute Rheumatic Fever: Novel Use of Hydroxychloroquine. ( Concannon, A; Davidakova, S; Malcolm, J; Martin, WJ; Moreland, NJ; Webb, R; Wilson, NJ, 2020) |
| " Therefore, if this unique immune quiescent state can be pharmacologically induced locally, it will provide an excellent women-oriented strategy against HIV infection To our knowledge, this is the first research article evaluating in vivo, an innovative trackable implant that can provide controlled delivery of hydroxychloroquine (HCQ) to successfully attenuate vaginal T lymphocyte activation and inflammation in a rabbit model as a potential strategy to induce an "immune quiescent" state within the FGT for the prevention of HIV infection." | 3.88 | Implant delivering hydroxychloroquine attenuates vaginal T lymphocyte activation and inflammation. ( Chen, Y; Fowke, KR; Ho, EA; Lajoie, J; Rickey, DW; Traore, YL; Yang, S, 2018) |
| " Hydroxychloroquine, an original antimalarial drug, prevents inflammation caused by lupus erythematosus and rheumatoid arthritis." | 3.83 | Hydroxychloroquine, a promising choice for coronary artery disease? ( Bai, X; Li, R; Liu, J; Liu, M; Ma, Q; Sun, L; Wei, Y; Wu, Y; Yang, Y; Yuan, Z; Zhang, L; Zhao, Q; Zhou, J, 2016) |
| " Hydroxychloroquine (HCQ), an anti-inflammatory drug, has been shown to have multiple pleiotropic actions relevant to atherosclerosis." | 3.81 | Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease. ( Apostolov, EO; Bose, C; Fahmi, T; Karaduta, OK; Kaushal, GP; Segal, MS; Shah, SV; Shukla, AM, 2015) |
| "Among patients with RA or psoriasis, the adjusted risk of DM was lower for individuals starting a TNF inhibitor or hydroxychloroquine compared with initiation of other nonbiologic DMARDs." | 3.77 | Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. ( Canning, C; Garg, R; Liu, J; Massarotti, E; Schneeweiss, S; Solomon, DH, 2011) |
| "Rheumatoid arthritis is a chronic, systemic inflammatory disease that carries an increased risk of mortality due to cardiovascular disease." | 2.72 | Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation. ( Chen, J; Cooper, D; Norling, LV, 2021) |
| "Hydroxychloroquine has been used for treating malaria, rheumatoid arthritis, and lupus." | 2.68 | Treatment for HIV-related inflammation. ( , 1995) |
| "The pandemic outbreak of coronavirus disease 2019 (COVID-19) is rapidly spreading all over the world." | 2.66 | The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. ( Li, T; Liu, Z; Qin, Y; Wang, J; Wang, Q; Yan, X; Zeng, X; Zhang, F; Zhang, S; Zhang, W; Zhang, X; Zhao, Y, 2020) |
| "Lupus pernio (LP) occurs in the form of smooth, bright nodules and plaques on the nose, ear, lips, and cheeks." | 1.56 | A case of chronic sarcoidosis presenting with lupus pernio. ( Duru Çetinkaya, P, 2020) |
| "The novel coronavirus disease 2019 (COVID-19) is a highly infectious and rapidly spreading disease." | 1.56 | Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report. ( Avdic, E; Avery, R; Cameron, AM; Chen, PH; Fine, DM; Garibaldi, B; Garneau, WM; Gurakar, A; Hammami, MB; Jain, T; Kim, AK; Liu, G; Monroy Trujillo, JM; Niranjan-Azadi, A; Petty, B; Shah, P; Strout, S, 2020) |
| "We hypothesized that patients with systemic lupus erythematosus (SLE) have greater blood pressure visit-to-visit variability than control subjects and that blood pressure visit-to-visit variability is associated with a higher comorbidity burden." | 1.51 | Increased blood pressure visit-to-visit variability in patients with systemic lupus erythematosus: association with inflammation and comorbidity burden. ( Barker, KA; Barnado, A; Chung, CP; Dickson, AL; Dupont, WD; Gandelman, JS; Khan, OA; Neal, JE; Reese, T; Shuey, MM; Stein, CM, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (7.94) | 18.7374 |
| 1990's | 2 (3.17) | 18.2507 |
| 2000's | 5 (7.94) | 29.6817 |
| 2010's | 16 (25.40) | 24.3611 |
| 2020's | 35 (55.56) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, J | 1 |
| Xiao, R | 1 |
| Zeng, R | 1 |
| He, E | 1 |
| Zhang, A | 1 |
| Akhtar, MF | 1 |
| Zubair, S | 1 |
| Saleem, A | 1 |
| Alsharif, KF | 1 |
| Abdel-Daim, MM | 1 |
| Yoshimizu, A | 1 |
| Kinoshita, K | 1 |
| Ichihara, Y | 1 |
| Kurauchi, Y | 1 |
| Seki, T | 1 |
| Katsuki, H | 1 |
| Zhu, X | 1 |
| Wang, Y | 1 |
| Xiao, Y | 1 |
| Gao, Q | 1 |
| Gao, L | 1 |
| Zhang, W | 2 |
| Xin, X | 1 |
| Chen, K | 1 |
| Srivastava, U | 1 |
| Ginjupalli, VKM | 1 |
| Cupelli, M | 1 |
| Lazzerini, PE | 1 |
| Capecchi, PL | 1 |
| Chen, L | 1 |
| Boutjdir, M | 1 |
| García, RD | 1 |
| Asensio, JA | 1 |
| Perdicaro, DJ | 1 |
| de Los Ángeles Peral, M | 1 |
| Ren, K | 1 |
| He, J | 1 |
| Qiu, Y | 1 |
| Xu, Z | 1 |
| Wang, X | 1 |
| Li, J | 4 |
| Zang, S | 1 |
| Yang, Y | 2 |
| Long, Y | 1 |
| Zhang, Z | 1 |
| Li, M | 1 |
| He, Q | 1 |
| Mikkelsen, RR | 1 |
| Hundahl, MP | 1 |
| Torp, CK | 1 |
| Rodríguez-Carrio, J | 1 |
| Kjolby, M | 1 |
| Bruun, JM | 1 |
| Kragstrup, TW | 1 |
| Caufriez, A | 1 |
| Tabernilla, A | 1 |
| Van Campenhout, R | 1 |
| Cooreman, A | 1 |
| Leroy, K | 1 |
| Sanz Serrano, J | 1 |
| Kadam, P | 1 |
| Dos Santos Rodrigues, B | 1 |
| Lamouroux, A | 1 |
| Ballet, S | 1 |
| Vinken, M | 1 |
| Li, S | 1 |
| Ma, R | 1 |
| Hu, XY | 1 |
| Li, HB | 1 |
| Geng, WC | 1 |
| Kong, X | 1 |
| Zhang, C | 1 |
| Guo, DS | 1 |
| Mathieu, S | 1 |
| Tournadre, A | 1 |
| Soubrier, M | 1 |
| Sellam, J | 1 |
| Kadife, E | 3 |
| Hannan, N | 3 |
| Harper, A | 3 |
| Binder, N | 3 |
| Beard, S | 3 |
| Brownfoot, FC | 3 |
| Atefi, N | 1 |
| Goodarzi, A | 1 |
| Riahi, T | 1 |
| Khodabandehloo, N | 1 |
| Talebi Taher, M | 1 |
| Najar Nobari, N | 1 |
| Seirafianpour, F | 1 |
| Mahdi, Z | 1 |
| Baghestani, A | 1 |
| Valizadeh, R | 1 |
| Gochuico, BR | 1 |
| Ziegler, SG | 1 |
| Ten, NS | 1 |
| Balanda, NJ | 1 |
| Mason, CE | 1 |
| Zumbo, P | 1 |
| Evans, CA | 1 |
| Van Waes, C | 1 |
| Gahl, WA | 1 |
| Malicdan, MCV | 1 |
| Duru Çetinkaya, P | 1 |
| Hu, TY | 1 |
| Frieman, M | 1 |
| Wolfram, J | 1 |
| Wilson, NJ | 1 |
| Concannon, A | 1 |
| Malcolm, J | 1 |
| Davidakova, S | 1 |
| Martin, WJ | 1 |
| Webb, R | 1 |
| Moreland, NJ | 1 |
| Zhao, Y | 1 |
| Zhang, F | 1 |
| Wang, Q | 1 |
| Li, T | 1 |
| Liu, Z | 1 |
| Wang, J | 1 |
| Qin, Y | 1 |
| Zhang, X | 1 |
| Yan, X | 1 |
| Zeng, X | 1 |
| Zhang, S | 1 |
| Lipworth, B | 1 |
| Chan, R | 1 |
| Lipworth, S | 1 |
| RuiWen Kuo, C | 1 |
| Hammami, MB | 1 |
| Garibaldi, B | 1 |
| Shah, P | 1 |
| Liu, G | 1 |
| Jain, T | 1 |
| Chen, PH | 1 |
| Kim, AK | 1 |
| Avdic, E | 1 |
| Petty, B | 1 |
| Strout, S | 1 |
| Fine, DM | 1 |
| Niranjan-Azadi, A | 1 |
| Garneau, WM | 1 |
| Cameron, AM | 1 |
| Monroy Trujillo, JM | 1 |
| Gurakar, A | 1 |
| Avery, R | 1 |
| Sciascia, S | 1 |
| Schreiber, K | 1 |
| Radin, M | 1 |
| Roccatello, D | 1 |
| Krämer, BK | 1 |
| Stach, K | 1 |
| Yu, B | 2 |
| Li, C | 2 |
| Chen, P | 2 |
| Zhou, N | 1 |
| Wang, L | 1 |
| Jiang, H | 2 |
| Wang, DW | 2 |
| Graef, ER | 1 |
| Liew, JW | 1 |
| Kim, AH | 1 |
| Sparks, JA | 1 |
| Erre, GL | 1 |
| Ferraccioli, ES | 1 |
| Piga, M | 1 |
| Mangoni, A | 1 |
| Passiu, G | 1 |
| Gremese, E | 1 |
| Ferraccioli, G | 1 |
| Kettelhut, A | 1 |
| Bowman, E | 1 |
| Funderburg, NT | 1 |
| Magro, G | 1 |
| Salacup, G | 1 |
| Lo, KB | 1 |
| Gul, F | 1 |
| Peterson, E | 1 |
| De Joy, R | 1 |
| Bhargav, R | 1 |
| Pelayo, J | 1 |
| Albano, J | 1 |
| Azmaiparashvili, Z | 1 |
| Benzaquen, S | 1 |
| Patarroyo-Aponte, G | 1 |
| Rangaswami, J | 1 |
| Ibrahim, H | 1 |
| Perl, A | 1 |
| Smith, D | 1 |
| Lewis, T | 1 |
| Kon, Z | 1 |
| Goldenberg, R | 1 |
| Yarta, K | 1 |
| Staniloae, C | 1 |
| Williams, M | 1 |
| Sciaccaluga, C | 1 |
| Cameli, M | 1 |
| Menci, D | 1 |
| Mandoli, GE | 1 |
| Sisti, N | 1 |
| Cameli, P | 1 |
| Franchi, F | 1 |
| Mondillo, S | 1 |
| Valente, S | 1 |
| Pandolfi, L | 1 |
| Fossali, T | 1 |
| Frangipane, V | 1 |
| Bozzini, S | 1 |
| Morosini, M | 1 |
| D'Amato, M | 1 |
| Lettieri, S | 1 |
| Urtis, M | 1 |
| Di Toro, A | 1 |
| Saracino, L | 1 |
| Percivalle, E | 1 |
| Tomaselli, S | 1 |
| Cavagna, L | 1 |
| Cova, E | 1 |
| Mojoli, F | 1 |
| Bergomi, P | 1 |
| Ottolina, D | 1 |
| Lilleri, D | 1 |
| Corsico, AG | 1 |
| Arbustini, E | 1 |
| Colombo, R | 1 |
| Meloni, F | 1 |
| Matangila, JR | 1 |
| Nyembu, RK | 1 |
| Telo, GM | 1 |
| Ngoy, CD | 1 |
| Sakobo, TM | 1 |
| Massolo, JM | 1 |
| Muyembe, BM | 1 |
| Mvwala, RK | 1 |
| Ilunga, CK | 1 |
| Limbole, EB | 1 |
| Ntalaja, JM | 1 |
| Kongo, RM | 1 |
| Toledo, FGS | 1 |
| Miller, RG | 1 |
| Helbling, NL | 1 |
| Zhang, Y | 1 |
| DeLany, JP | 1 |
| Ogah, OS | 1 |
| Umuerri, EM | 1 |
| Adebiyi, A | 1 |
| Orimolade, OA | 1 |
| Sani, MU | 1 |
| Ojji, DB | 1 |
| Mbakwem, AC | 1 |
| Stewart, S | 1 |
| Sliwa, K | 1 |
| Chen, J | 1 |
| Norling, LV | 1 |
| Cooper, D | 1 |
| Barratt-Due, A | 1 |
| Olsen, IC | 1 |
| Nezvalova-Henriksen, K | 1 |
| Kåsine, T | 1 |
| Lund-Johansen, F | 1 |
| Hoel, H | 1 |
| Holten, AR | 1 |
| Tveita, A | 1 |
| Mathiessen, A | 1 |
| Haugli, M | 1 |
| Eiken, R | 1 |
| Kildal, AB | 1 |
| Berg, Å | 1 |
| Johannessen, A | 1 |
| Heggelund, L | 1 |
| Dahl, TB | 1 |
| Skåra, KH | 1 |
| Mielnik, P | 1 |
| Le, LAK | 1 |
| Thoresen, L | 1 |
| Ernst, G | 1 |
| Hoff, DAL | 1 |
| Skudal, H | 1 |
| Kittang, BR | 1 |
| Olsen, RB | 1 |
| Tholin, B | 1 |
| Ystrøm, CM | 1 |
| Skei, NV | 1 |
| Tran, T | 1 |
| Dudman, S | 1 |
| Andersen, JT | 1 |
| Hannula, R | 1 |
| Dalgard, O | 1 |
| Finbråten, AK | 1 |
| Tonby, K | 1 |
| Blomberg, B | 1 |
| Aballi, S | 1 |
| Fladeby, C | 1 |
| Steffensen, A | 1 |
| Müller, F | 1 |
| Dyrhol-Riise, AM | 1 |
| Trøseid, M | 1 |
| Aukrust, P | 1 |
| Poorvashree, J | 1 |
| Suneela, D | 1 |
| Chen, Y | 1 |
| Traore, YL | 1 |
| Yang, S | 1 |
| Lajoie, J | 1 |
| Fowke, KR | 1 |
| Rickey, DW | 1 |
| Ho, EA | 1 |
| Rodrigues, JC | 1 |
| Bargman, JM | 1 |
| Torigoe, M | 1 |
| Sakata, K | 1 |
| Ishii, A | 1 |
| Iwata, S | 1 |
| Nakayamada, S | 1 |
| Tanaka, Y | 1 |
| Reese, T | 1 |
| Dickson, AL | 1 |
| Shuey, MM | 1 |
| Gandelman, JS | 1 |
| Barnado, A | 1 |
| Barker, KA | 1 |
| Neal, JE | 1 |
| Khan, OA | 1 |
| Dupont, WD | 1 |
| Stein, CM | 1 |
| Chung, CP | 1 |
| Lenert, P | 1 |
| Icardi, M | 1 |
| Dahmoush, L | 1 |
| Shukla, AM | 1 |
| Bose, C | 1 |
| Karaduta, OK | 1 |
| Apostolov, EO | 1 |
| Kaushal, GP | 1 |
| Fahmi, T | 1 |
| Segal, MS | 1 |
| Shah, SV | 1 |
| Chaturvedi, S | 1 |
| McCrae, KR | 1 |
| Yao, J | 1 |
| Xie, J | 1 |
| Xie, B | 1 |
| Li, Y | 1 |
| Jiang, L | 1 |
| Sui, X | 1 |
| Zhou, X | 1 |
| Pan, H | 1 |
| Han, W | 1 |
| Sun, L | 1 |
| Liu, M | 1 |
| Li, R | 1 |
| Zhao, Q | 1 |
| Liu, J | 2 |
| Zhang, L | 1 |
| Bai, X | 1 |
| Wei, Y | 1 |
| Ma, Q | 1 |
| Zhou, J | 1 |
| Yuan, Z | 1 |
| Wu, Y | 1 |
| Amaravadi, RK | 1 |
| Lippincott-Schwartz, J | 1 |
| Yin, XM | 1 |
| Weiss, WA | 1 |
| Takebe, N | 1 |
| Timmer, W | 1 |
| DiPaola, RS | 1 |
| Lotze, MT | 1 |
| White, E | 1 |
| Solomon, DH | 1 |
| Massarotti, E | 1 |
| Garg, R | 1 |
| Canning, C | 1 |
| Schneeweiss, S | 1 |
| Bongartz, T | 1 |
| Kudva, Y | 1 |
| Paton, NI | 1 |
| Goodall, RL | 1 |
| Dunn, DT | 1 |
| Franzen, S | 1 |
| Collaco-Moraes, Y | 1 |
| Gazzard, BG | 1 |
| Williams, IG | 1 |
| Fisher, MJ | 1 |
| Winston, A | 1 |
| Fox, J | 1 |
| Orkin, C | 1 |
| Herieka, EA | 1 |
| Ainsworth, JG | 1 |
| Post, FA | 1 |
| Wansbrough-Jones, M | 1 |
| Kelleher, P | 1 |
| Stein, JH | 1 |
| Hsue, PY | 1 |
| Massanella, M | 1 |
| Negredo, E | 1 |
| Puig, J | 1 |
| Puertas, MC | 1 |
| Buzón, MJ | 1 |
| Pérez-Álvarez, N | 1 |
| Carrillo, J | 1 |
| Clotet, B | 1 |
| Martínez-Picado, J | 1 |
| Blanco, J | 1 |
| DIMATTEI, P | 1 |
| Knight, AK | 1 |
| Cunningham-Rundles, C | 1 |
| Elmore, S | 1 |
| Lanning, L | 1 |
| Allison, N | 1 |
| Vallant, M | 1 |
| Nyska, A | 1 |
| Tweezer-Zaks, N | 1 |
| Ben-Horin, S | 1 |
| Schiby, G | 1 |
| Bank, I | 1 |
| Levi, Y | 1 |
| Livneh, A | 1 |
| Langevitz, P | 1 |
| Bouaziz, JD | 1 |
| Barete, S | 1 |
| Le Pelletier, F | 1 |
| Amoura, Z | 1 |
| Piette, JC | 1 |
| Francès, C | 1 |
| Flach, AJ | 1 |
| Lanham, JG | 1 |
| Hughes, GR | 1 |
| Clarke, AK | 1 |
| Vernon-Roberts, B | 1 |
| Currey, HL | 1 |
| Charous, BL | 1 |
| Jolles, B | 1 |
| Harrison, RG | 1 |
| Jobin, F | 1 |
| Gagnon, FT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of the Use of Hydroxychloroquine, Favipiravir or Hydroxychloroquine + Favipiravir in Early SARS-CoV-2 (COVID-19) Treatment[NCT04981379] | Phase 3 | 1,120 participants (Actual) | Interventional | 2020-11-16 | Completed | ||
| Nutritional Habits, Does it Affect Coronavirus Disease 2019 (COVID-19) Infection Outcome? An Egyptian Experience[NCT04447144] | 200 participants (Anticipated) | Observational | 2020-06-01 | Recruiting | |||
| Evaluation of Independent Clinical- Laboratory Predictors of Clinical Outcomes in Hospitalized Positive SARS-CoV2 Patients (Outcomes SARS-CoV2)[NCT05162534] | 1,800 participants (Actual) | Observational | 2020-05-29 | Completed | |||
| Comparison of Cytokine Hemadsorption as an Immunomodulator Therapy in Covid 19 Patients With and Without Bacterial Sepsis[NCT04920851] | 23 participants (Anticipated) | Observational | 2021-06-10 | Recruiting | |||
| Evaluation of a New Score Incorporating Endothelial Dysfunction for the Assessment of Coronary Heart Disease Risk in Patients With Rheumatoid Arthritis: a 3-year Prospective Study.[NCT02341066] | 3,000 participants (Anticipated) | Observational | 2015-07-31 | Recruiting | |||
| The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients[NCT04321616] | Phase 2/Phase 3 | 700 participants (Anticipated) | Interventional | 2020-03-28 | Recruiting | ||
| PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) A Double-blind Placebo Controlled Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19[NCT04353037] | Phase 2 | 39 participants (Actual) | Interventional | 2020-04-07 | Terminated (stopped due to As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants.) | ||
| Impact of Rheumatoid Arthritis on Type 2 Diabetes Mellitus[NCT02639988] | 1,000 participants (Anticipated) | Observational | 2016-04-13 | Suspended | |||
| Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis: A Prospective Randomized Double Blind Controlled Study[NCT02644954] | Phase 3 | 40 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection[NCT02475915] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 1-3 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 4 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 15-17 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 6 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Co-inhabitants of COVID-19 positive PCR patients in self-quarantine that test positive up to 31 days after patient begins treatment with HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
if the participant gets COVID and has severe symptoms and hospitalized, end point reached if before the end of the 2 month period (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Number of COVID-19+ PCR patients in self-quarantine who are hospitalized up to 31 days after beginning HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Assessment of any medical events that occur during the ~60 day active period that is felt to be related to receipt of HCQ (NCT04353037)
Timeframe: Until completion of study, 2 months (~60 days) after start of treatment.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| moderate adverse events | minor adverse events | |
| Sub Study 2 Group 1 (HCQ) | 2 | 1 |
| Sub Study 2 Group 2 (Placebo) | 0 | 0 |
15 reviews available for hydroxychloroquine and Innate Inflammatory Response
| Article | Year |
|---|---|
Small molecules targeting cGAS-STING pathway for autoimmune disease.
Topics: Autoimmune Diseases; Humans; Inflammation; Membrane Proteins; Nucleotidyltransferases; Signal Transd | 2022 |
The Role of Inflammation as a Preponderant Risk Factor in Cardiovascular Diseases.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hydroxychloroqui | 2022 |
Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Colchicine; Diabetes Mellitus, | 2022 |
Effect of disease-modifying anti-rheumatic drugs in osteoarthritis: A meta-analysis.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Inflammation; Interleukin-1; Methotrexate; Osteoar | 2022 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chloroquine; Coronavir | 2020 |
Immunomodulatory and Anti-Inflammatory Strategies to Reduce Comorbidity Risk in People with HIV.
Topics: Anti-Inflammatory Agents; Anti-Retroviral Agents; Antibodies, Monoclonal, Humanized; Comorbidity; Ga | 2020 |
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Mono | 2020 |
COVID-19 and the burning issue of drug interaction: never forget the ECG.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral | 2021 |
SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications.
Topics: Acute Coronary Syndrome; Africa; Antimalarials; Arrhythmias, Cardiac; Cardiovascular Diseases; Chlor | 2021 |
Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheuma | 2021 |
ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review.
Topics: Acne Vulgaris; Angiography; Antibodies, Antineutrophil Cytoplasmic; Autoimmunity; Biopsy; Diagnosis, | 2013 |
The antiphospholipid syndrome: still an enigma.
Topics: Administration, Oral; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; beta | 2015 |
Principles and current strategies for targeting autophagy for cancer treatment.
Topics: Animals; Antineoplastic Agents; Autophagy; Clinical Trials, Phase III as Topic; Combined Modality Th | 2011 |
Inflammatory and autoimmune complications of common variable immune deficiency.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2006 |
Antimalarial therapy in SLE.
Topics: Antimalarials; Binding Sites; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Femal | 1982 |
6 trials available for hydroxychloroquine and Innate Inflammatory Response
| Article | Year |
|---|---|
Evaluation of the efficacy and safety of oral N-acetylcysteine in patients with COVID-19 receiving the routine antiviral and hydroxychloroquine protocol: A randomized controlled clinical trial.
Topics: Acetylcysteine; Antiviral Agents; Atazanavir Sulfate; C-Reactive Protein; COVID-19; COVID-19 Drug Tr | 2023 |
The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: A randomized trial.
Topics: Adult; Diabetes Mellitus, Type 2; Humans; Hydroxychloroquine; Inflammation; Insulin; Insulin Resista | 2021 |
Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Viral; Antiviral Agents; Biomarkers; Cause of Death; C | 2021 |
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; CD8-Posit | 2012 |
Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphoc | 2012 |
Treatment for HIV-related inflammation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; CD4 Lymphocyte Count; Double-Blind Method | 1995 |
42 other studies available for hydroxychloroquine and Innate Inflammatory Response
| Article | Year |
|---|---|
Comparison of individual and combination treatments with naproxen, prednisolone and hydroxychloroquine to treat Complete Freund's Adjuvant induced arthritis.
Topics: Animals; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Experimental; Erythrocytes; Fema | 2021 |
Hydroxychloroquine improves motor function and affords neuroprotection without inhibition of inflammation and autophagy in mice after intracerebral hemorrhage.
Topics: Animals; Autophagy; Brain; Cerebral Hemorrhage; Hydroxychloroquine; Inflammation; Male; Mice; Mice, | 2022 |
Arrhythmogenic mechanisms of interleukin-6 combination with hydroxychloroquine and azithromycin in inflammatory diseases.
Topics: Animals; Antibodies, Monoclonal, Humanized; Arrhythmias, Cardiac; Azithromycin; COVID-19; COVID-19 D | 2022 |
A neutrophil-mediated carrier regulates tumor stemness by inhibiting autophagy to prevent postoperative triple-negative breast cancer recurrence and metastasis.
Topics: Autophagy; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Hydroxychloroquine; Inflammation; Lip | 2022 |
Effects of Drugs Formerly Suggested for COVID-19 Repurposing on Pannexin1 Channels.
Topics: Connexins; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydroxychloroquine; Inflammation; Lo | 2022 |
Drug in Drug: A Host-Guest Formulation of Azocalixarene with Hydroxychloroquine for Synergistic Anti-Inflammation.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Hydroxychloroquine; Inflammation; Pharmace | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro.
Topics: Biomarkers; Endoglin; Endothelial Cells; Female; Humans; Hydroxychloroquine; Inflammation; Placenta; | 2022 |
A comprehensive, multidisciplinary, precision medicine approach to discover effective therapy for an undiagnosed, progressive, fibroinflammatory disease.
Topics: Adolescent; Bronchoalveolar Lavage Fluid; Disease Progression; Female; Fibroblasts; Fibrosis; Gene E | 2020 |
A case of chronic sarcoidosis presenting with lupus pernio.
Topics: Antirheumatic Agents; Biopsy; Chilblains; Diagnosis, Differential; Female; Humans; Hydroxychloroquin | 2020 |
Insights from nanomedicine into chloroquine efficacy against COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Trea | 2020 |
The Treatment of Acute Rheumatic Fever: Novel Use of Hydroxychloroquine.
Topics: Adolescent; Antirheumatic Agents; Biomarkers; Child; Humans; Hydroxychloroquine; Inflammation; Inter | 2020 |
Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Age Factors; Angiotensin-Converting Enzyme Inhi | 2020 |
Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report.
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Coronavirus Infections; COVID-19; COVI | 2020 |
Hydroxychloroquine reduces IL-6 and pro-thrombotic status.
Topics: Human Umbilical Vein Endothelial Cells; Humans; Hydroxychloroquine; Inflammation; Interleukin-6; Lup | 2020 |
Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19.
Topics: China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Humans; Hydroxyc | 2020 |
Response to: 'Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?' by Erre
Topics: Antimalarials; Arrhythmias, Cardiac; COVID-19; Humans; Hydroxychloroquine; Inflammation; Rheumatic D | 2021 |
Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?
Topics: Antimalarials; Antirheumatic Agents; Arrhythmias, Cardiac; COVID-19; Humans; Hydroxychloroquine; Inf | 2021 |
Characteristics and clinical outcomes of COVID-19 patients in an underserved-inner city population: A single tertiary center cohort.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antimalarials; | 2021 |
Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine.
Topics: Acetylcysteine; Adult; Antioxidants; Antirheumatic Agents; Betacoronavirus; Biomarkers; C-Reactive P | 2020 |
Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs.
Topics: Aged; Antimalarials; Antiviral Agents; China; COVID-19 Drug Treatment; Critical Illness; Female; Hum | 2021 |
Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Aged; Alanine; Antibodies, Monoclonal, Humanized; | 2020 |
Clinical characteristics of COVID-19 patients hospitalized at Clinique Ngaliema, a public hospital in Kinshasa, in the Democratic Republic of Congo: A retrospective cohort study.
Topics: Adult; Aged; Blood Coagulation; Chloroquine; Coinfection; Comorbidity; Cough; COVID-19; COVID-19 Dru | 2020 |
Novel drug delivery of dual acting prodrugs of hydroxychloroquine with aryl acetic acid NSAIDs: Design, kinetics and pharmacological study.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthritis, R | 2017 |
Implant delivering hydroxychloroquine attenuates vaginal T lymphocyte activation and inflammation.
Topics: Administration, Intravaginal; Animals; Drug Delivery Systems; Drug Implants; Female; Hydroxychloroqu | 2018 |
Antimalarial Drugs for the Prevention of Chronic Kidney Disease in Patients with Rheumatoid Arthritis: The Importance of Controlling Chronic Inflammation?
Topics: Antimalarials; Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Inflammation; Renal Insufficiency, | 2018 |
Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition.
Topics: Anti-Inflammatory Agents; Antibody Formation; Antigens, CD19; B-Lymphocyte Subsets; B-Lymphocytes; C | 2018 |
Increased blood pressure visit-to-visit variability in patients with systemic lupus erythematosus: association with inflammation and comorbidity burden.
Topics: Adrenal Cortex Hormones; Adult; Blood Pressure; Case-Control Studies; Comorbidity; Cyclophosphamide; | 2019 |
Impact of Hydroxychloroquine on Atherosclerosis and Vascular Stiffness in the Presence of Chronic Kidney Disease.
Topics: Animals; Aorta; Atherosclerosis; Bilirubin; Blood Glucose; Elasticity; Hydroxychloroquine; Inflammat | 2015 |
Therapeutic effect of hydroxychloroquine on colorectal carcinogenesis in experimental murine colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinogenesis; Cell Proliferation; Colitis; Color | 2016 |
Hydroxychloroquine, a promising choice for coronary artery disease?
Topics: Animals; Antimalarials; Arthritis, Rheumatoid; Coronary Artery Disease; Disease Models, Animal; Huma | 2016 |
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Cohort Studies; Diabetes Mellitus; Female | 2011 |
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Cohort Studies; Diabetes Mellitus; Female | 2011 |
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Cohort Studies; Diabetes Mellitus; Female | 2011 |
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Cohort Studies; Diabetes Mellitus; Female | 2011 |
Can treatment of chronic inflammatory diseases reduce the risk of diabetes mellitus?
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Hu | 2011 |
Inflammation, immune activation, and CVD risk in individuals with HIV infection.
Topics: Anti-Inflammatory Agents; Aorta; Cardiovascular Diseases; Female; HIV Infections; Humans; Hydroxychl | 2012 |
[PHARMACOLOGY AND CHRONIC INFLAMMATIONS].
Topics: Arthritis; Arthritis, Rheumatoid; Drug Therapy; Granuloma; Hydroxychloroquine; Inflammation; Iodides | 1963 |
The transduction of rat submandibular glands by an adenoviral vector carrying the human growth hormone gene is associated with limited and reversible changes at the infusion site.
Topics: Adenoviridae; Animals; Antirheumatic Agents; Female; Fibrosis; Gene Transfer Techniques; Genetic Vec | 2006 |
Severe gastrointestinal inflammation in adult dermatomyositis: characterization of a novel clinical association.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Cyclophosphamide; Dermatomyositis; Fatal Outcome; Fem | 2006 |
Cutaneous lesions of the digits in systemic lupus erythematosus: 50 cases.
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Chilblains; Child; Cohort St | 2007 |
Improving the risk-benefit relationship and informed consent for patients treated with hydroxychloroquine.
Topics: Arthritis, Rheumatoid; Chloroquine; Humans; Hydroxychloroquine; Inflammation; Informed Consent; Lupu | 2007 |
Assessment of anti-inflammatory drugs in the rat using subcutaneous implants of polyurethane foam impregnated with dead tubercle bacilli.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Azathioprine; Biological Assay; Cyclophosphamide; Female | 1975 |
Effectiveness of long-term treatment of severe asthma with hydroxychloroquine (HCQ).
Topics: Asthma; Follow-Up Studies; Forced Expiratory Flow Rates; Humans; Hydroxychloroquine; Inflammation | 1991 |
Enzymic processes and vascular changes in the skin radiation reaction.
Topics: Aminocaproates; Animals; Capillary Permeability; Guinea Pigs; Histamine H1 Antagonists; Hydroxychlor | 1966 |
Platelet reactions and immune processes. IV. The inhibition of complement by pyrazole compounds and other inhibitors of platelet reactions.
Topics: Animals; Blood Coagulation; Blood Platelets; Chloroquine; Complement Inactivator Proteins; Erythrocy | 1970 |